Decreased neutrophil-to-lymphocyte ratio predicted cognitive improvement in late-life depression treated with vortioxetine: Findings from an eight-week randomized controlled trial

被引：0
作者：
Xue, Lingfeng [1 ]
Lewis, Elin [2 ]
Bocharova, Mariia [1 ]
Young, Allan H. [3 ]
Aarsland, Dag [1 ]
机构：
[1] Kings Coll London, Inst Psychiat Psychol & Neurosci, Ctr Hlth Brain Ageing, London SE5 8AF, England
[2] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Psychol Med, London SE5 8AF, England
[3] Kings Coll London, Inst Psychiat Psychol & Neurosci, Ctr Affect Disorders, London SE5 8AF, England
来源：
BRAIN BEHAVIOR AND IMMUNITY | 2025年 / 126卷
关键词：
Late-life depression; Vortioxetine; Neutrophil-to-lymphocyte ratio; Cognition; Inflammation; LU AA21004; ANTIDEPRESSANT TREATMENT; INFLAMMATORY MARKERS; PERIPHERAL CYTOKINE; PLATELET-LYMPHOCYTE; DOUBLE-BLIND; METAANALYSIS; SEVERITY;
D O I：
10.1016/j.bbi.2025.01.029
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Background: Elevated neutrophil-to-lymphocyte ratio, a marker of inflammation, has been reported in adult and late-life depression. Vortioxetine has shown efficacy in treatment of late-life depression, yet little is known regarding its immunomodulatory role in clinical trials. Methods: This is a post-hoc analysis of an eight-week randomized controlled trial. Depressed patients aged 65 or above were treated by vortioxetine, duloxetine or placebo. 321 patients that have taken blood tests at baseline and endpoint were included in the analysis. Neutrophil-to-lymphocyte ratio (NLR) was calculated using the absolute counts of each cell type. Cognitive performance was assessed by composite score of Digit Symbol Substitution Test (DSST) and the Rey Auditory Verbal Learning Test (RAVLT) tasks, while depressive symptoms were assessed by Montgomery-& Aring;sberg Depression Rating Scale (MADRS) and Geriatric Depression Scale (GDS). Results: NLR levels decreased significantly in the entire analysis set (t(320) = 2.64, p = 0.008) and in the vortioxetine group (M = -0.186, t(105) = 2.070, p = 0.041, Cohen's d = 0.20), but not in the two other groups. This decrease was not significantly different compared to placebo (F(1, 213) = 0.420, p = 0.517). Furthermore, larger NLR changes in vortioxetine arm predicted significant cognitive improvement (3 = -4.03, p = 0.03), specifically regarding the DSST correct symbols (3 = -1.97, p = 0.04) and RAVLT delayed recall (3 = -1.87, p = 0.02) tasks. Additionally, decreased NLR significantly predicted reduced GDS score (3 = 1.82, p = 0.02), yet not MADRS score. Conclusion: Vortioxetine treatment was associated with decreased NLR levels in late-life depression, and reductions in NLR predicted improvements in cognitive function and depressive symptoms, suggesting a potential link between inflammation and clinical outcomes.
引用
收藏
页码：53 / 58
页数：6
相关论文
共 53 条
  • [21] Henigsberg N., Mahableshwarkar A.R., Jacobsen P., Chen Y., Thase M.E., A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder, J. Clin. Psychiatry, 73, 7, (2012)
  • [22] Hlavacova N., Li Y., Pehrson A., Sanchez C., Bermudez-Diaz I., Csanova A., Et al., Effects of vortioxetine on biomarkers associated with glutamatergic activity in an SSRI insensitive model of depression in female rats, Prog. Neuropsychopharmacol. Biol. Psychiatry, (2018)
  • [23] Jaeger J., Digit symbol substitution test: the case for sensitivity over specificity in neuropsychological testing, J. Clin. Psychopharmacol., 38, 5, pp. 513-519, (2018)
  • [24] Katona C., Hansen T., Olsen C.K., A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder, Int. Clin. Psychopharmacol., 27, 4, pp. 215-223, (2012)
  • [25] Kayhan F., Gunduz S., Ersoy S.A., Kandeger A., Annagur B.B., Relationships of neutrophil–lymphocyte and platelet–lymphocyte ratios with the severity of major depression, Psychiatry Res., 247, pp. 332-335, (2017)
  • [26] Kofod J., Elfving B., Nielsen E.H., Mors O., Kohler-Forsberg O., Depression and inflammation: correlation between changes in inflammatory markers with antidepressant response and long-term prognosis, Eur. Neuropsychopharmacol., 54, pp. 116-125, (2022)
  • [27] Kohler C.A., Freitas T.H., Maes M., De Andrade N., Liu C.S., Fernandes B.S., Et al., Peripheral cytokine and chemokine alterations in depression: a meta‐analysis of 82 studies, Acta Psychiatr. Scand., 135, 5, pp. 373-387, (2017)
  • [28] Kwan A.T.H., Guo Z., Ceban F., Le G.H., Wong S., Teopiz K.M., Et al., Assessing the effects of metabolic disruption, body mass index and inflammation on depressive symptoms in post-COVID-19 condition: a randomized controlled trial on vortioxetine, Adv. Ther., 41, 5, pp. 1983-1994, (2024)
  • [29] Liu J.J., Wei Y.B., Strawbridge R., Bao Y., Chang S., Shi L., Et al., Peripheral cytokine levels and response to antidepressant treatment in depression: a systematic review and meta-analysis, Mol. Psychiatry, 25, 2, pp. 339-350, (2020)
  • [30] Lucin K.M., Wyss-Coray T., Immune activation in brain aging and neurodegeneration: too much or too little?, Neuron, 64, 1, pp. 110-122, (2009)
123456